Editas signs genome-edited stem cell pact with GSK, Biogen biotech partner – FierceBiotech
FierceBiotech |
Editas signs genome-edited stem cell pact with GSK, Biogen biotech partner
FierceBiotech Gene editing biotech Editas Medicine ($EDIT) has signed a three-year R&D collab deal with Milan-based San Raffaele Telethon Institute for Gene Therapy to develop next-gen stem and T-cell therapies. The Italian institute (also known as SR-TIGET)–which … Editas teams up with Italian gene therapy institute |
